Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 692 | 92 | 591 |
| Samples | 261 | 48 | 209 |
| Peptides | 210 | 28 | 184 |
Function
TAB2 · TGF-beta activated kinase 1 (MAP3K7) binding protein 2
The protein encoded by this gene is an activator of MAP3K7/TAK1, which is required for for the IL-1 induced activation of nuclear factor kappaB and MAPK8/JNK. This protein forms a kinase complex with TRAF6, MAP3K7 and TAB1, and it thus serves as an adaptor that links MAP3K7 and TRAF6. This protein, along with TAB1 and MAP3K7, also participates in the signal transduction induced by TNFSF11/RANKl through the activation of the receptor activator of NF-kappaB (TNFRSF11A/RANK), which may regulate the development and function of osteoclasts. Studies of the related mouse protein indicate that it functions to protect against liver damage caused by chemical stressors. Mutations in this gene cause congenital heart defects, multiple types, 2 (CHTD2). Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000637181 | Q9NYJ8 | 281 | 208 |
| ENST00000367456 | Q9NYJ8 | 257 | 200 |
| ENST00000636456 | A0A1B0GV57* | 154 | 122 |
Gene Properties
Recurrent Mutations
All 208 amino-acid changes on canonical ENST00000637181 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TAB2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TAB2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 20/612 3% |
| Cervical Carcinoma | 0/35 0% | 7/422 2% |
| Melanoma | 0/210 0% | 26/1899 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Non-Small Cell Lung Carcinoma | 10/304 3% | 9/1390 1% |
| Colorectal Carcinoma | 6/143 4% | 30/3239 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Gastric Carcinoma | 4/74 5% | 15/1809 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 7/810 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Bladder Carcinoma | 1/58 2% | 6/956 1% |
| Hepatocellular Carcinoma | 2/46 4% | 13/2210 1% |
| Ovarian Carcinoma | 5/109 5% | 2/998 0% |
| Plasma Cell Myeloma | 1/44 2% | 1/305 0% |
| Neuroendocrine Tumour | 3/154 2% | 1/577 0% |
| Head and Neck Carcinoma | 0/85 0% | 9/1574 1% |
| Small Cell Lung Carcinoma | 1/9 11% | 3/752 0% |
| Biliary Tract Carcinoma | 0/54 0% | 5/950 1% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Mesothelioma | 0/62 0% | 1/165 1% |
| Other Sarcomas | 1/69 1% | 2/699 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Other Solid Cancers | 0/94 0% | 6/1515 0% |
| Breast Carcinoma | 2/144 1% | 10/3264 0% |
| Kidney Carcinoma | 1/85 1% | 5/1862 0% |
| Pancreatic Carcinoma | 3/89 3% | 1/1611 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 6/2550 0% |
| Wilms Tumour | 0/5 0% | 1/474 0% |
Mutation Distribution
Where TAB2 is mutated · all tissues, split by cell line vs tissue
How many mutations in TAB2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 692 mutations in TAB2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|